MLTX insider transaction filings
MoonLake Immunotherapeutics — 40 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-29. Screen MLTX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-29 | 4 | Reich Kristian — Chief Scientific Officer | Sale (S): 1,100 @ $20 | EDGAR |
| 2026-07-23 | 4 | Reich Kristian — Chief Scientific Officer | Sale (S): 50,000 @ $20.02 · Sale (S): 2,448 @ $20 | EDGAR |
| 2026-07-21 | 4 | Reich Kristian — Chief Scientific Officer | Sale (S): 43,700 @ $20.09 | EDGAR |
| 2026-07-20 | 4 | Reich Kristian — Chief Scientific Officer | Sale (S): 16,105 @ $20.01 | EDGAR |
| 2026-07-13 | 4 | Santos da Silva Jorge — Chief Executive Officer, Director | Sale (S): 33,936 @ $20.01 · Sale (S): 68,289 @ $20.02 | EDGAR |
| 2026-07-02 | 4 | Santos da Silva Jorge — Chief Executive Officer, Director | Sale (S): 47,775 @ $20.03 | EDGAR |
| 2026-06-23 | 4 | Bodenstedt Matthias — Chief Financial Officer | Sale (S): 39,120 @ $22.04 | EDGAR |
| 2026-06-22 | 4 | BVF PARTNERS L P/IL — Director, 10% owner BIOTECHNOLOGY VALUE FUND L P — Director, 10% owner BVF I GP LLC — Director, 10% owner BIOTECHNOLOGY VALUE FUND II LP — Director BVF II GP LLC — Director Biotechnology Value Trading Fund OS LP — Director BVF Partners OS Ltd. — Director BVF GP HOLDINGS LLC — Director, 10% owner BVF INC/IL — Director, 10% owner LAMPERT MARK N — Director, 10% owner | Grant/award (A): 22,195 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Bodenstedt Matthias — Chief Financial Officer | Sale (S): 15,082 @ $19.68 · Sale (S): 2,794 @ $19.60 | EDGAR |
| 2026-06-18 | 4 | Phillips Andrew John — Director | Grant/award (A): 22,195 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Loy Spike — Director | Grant/award (A): 22,195 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Xavier Ramnik — Director | Grant/award (A): 22,195 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Moukheibir Catherine — Director | Grant/award (A): 22,195 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Reich Kristian — Chief Scientific Officer | Sale (S): 50,000 @ $18.89 · Sale (S): 50,000 @ $18.70 · Sale (S): 50,000 @ $19.43 | EDGAR |
| 2026-05-13 | 4 | Bodenstedt Matthias — Chief Financial Officer | Sale (S): 13,653 @ $20.02 | EDGAR |
| 2026-04-16 | 4 | Bodenstedt Matthias — Chief Financial Officer | Sale (S): 2,426 @ $19.56 | EDGAR |
| 2026-04-14 | 4 | Santos da Silva Jorge — Chief Executive Officer, Director | Sale (S): 98,127 @ $18.41 · Sale (S): 51,873 @ $18.23 | EDGAR |
| 2026-04-10 | 4 | Bodenstedt Matthias — Chief Financial Officer | Sale (S): 85,870 @ $18.94 · Sale (S): 1,925 @ $19.51 | EDGAR |
| 2026-04-02 | 4 | BVF PARTNERS L P/IL — Director, 10% owner BIOTECHNOLOGY VALUE FUND L P — Director, 10% owner BVF I GP LLC — Director, 10% owner BIOTECHNOLOGY VALUE FUND II LP — Director, 10% owner BVF II GP LLC — Director, 10% owner Biotechnology Value Trading Fund OS LP — Director BVF Partners OS Ltd. — Director BVF GP HOLDINGS LLC — Director, 10% owner BVF INC/IL — Director, 10% owner LAMPERT MARK N — Director, 10% owner | Sale (S): 1,932,354 @ $16.79 · Sale (S): 1,569,116 @ $16.79 · Sale (S): 248,530 @ $16.79 | EDGAR |
| 2026-01-09 | 4 | Bodenstedt Matthias — Chief Financial Officer | Grant/award (A): 354,296 @ $0 | EDGAR |
| 2026-01-09 | 4 | Santos da Silva Jorge — Chief Executive Officer, Director | Grant/award (A): 520,342 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Reich Kristian — Chief Scientific Officer | Grant/award (A): 520,342 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Bodenstedt Matthias — Chief Financial Officer | Conversion (C): 294,473 · Disposition to issuer (D): 294,473 · Conversion (C): 8,754 (derivative) | EDGAR |
| 2025-12-22 | 4 | Reich Kristian — Chief Scientific Officer | Conversion (C): 35,389 · Disposition to issuer (D): 35,389 · Conversion (C): 1,052 (derivative) | EDGAR |
| 2025-12-22 | 4 | Santos da Silva Jorge — Chief Executive Officer, Director | Conversion (C): 196,316 · Disposition to issuer (D): 196,316 · Conversion (C): 5,836 (derivative) | EDGAR |
| 2025-12-10 | 4 | Santos da Silva Jorge — Chief Executive Officer, Director | Sale (S): 130,000 @ $15.08 · Sale (S): 70,000 @ $14.49 | EDGAR |
| 2025-12-10 | 4 | Reich Kristian — Chief Scientific Officer | Sale (S): 130,000 @ $15.08 · Sale (S): 72,908 @ $14.43 | EDGAR |
| 2025-10-09 | 4 | Bodenstedt Matthias — Chief Financial Officer | Purchase (P): 10,870 @ $9.09 | EDGAR |
| 2025-10-01 | 4 | Chen Bihua Cormorant Asset Management, LP Cormorant Global Healthcare Master Fund, LP Cormorant Private Healthcare Fund II, LP Cormorant Private Healthcare Fund III LP Cormorant Private Healthcare Fund IV LP | Sale (S): 70,748 @ $9.38 · Sale (S): 232,460 @ $8.40 · Sale (S): 3,390,943 @ $7.58 · Sale (S): 2,800,000 @ $6.61 · Sale (S): 5,827 @ $6.96 | EDGAR |
| 2025-09-04 | 4 | Reich Kristian — Chief Scientific Officer | Conversion (C): 48,978 · Disposition to issuer (D): 48,978 · Conversion (C): 1,456 (derivative) | EDGAR |
| 2025-07-07 | 4 | Moukheibir Catherine — Director | Option exercise (M): 23,500 @ $0 · Sale (S): 23,500 @ $48.79 · Option exercise (M): 23,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Sturge Simon — Director | Grant/award (A): 6,682 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Loy Spike — Director | Grant/award (A): 6,682 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Xavier Ramnik — Director | Grant/award (A): 6,682 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Phillips Andrew John — Director | Grant/award (A): 6,682 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Moukheibir Catherine — Director | Grant/award (A): 6,682 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | BVF PARTNERS L P/IL — Director, 10% owner BIOTECHNOLOGY VALUE FUND L P — Director, 10% owner BVF I GP LLC — Director, 10% owner BIOTECHNOLOGY VALUE FUND II LP — Director, 10% owner BVF II GP LLC — Director, 10% owner Biotechnology Value Trading Fund OS LP — Director BVF Partners OS Ltd. — Director BVF GP HOLDINGS LLC — Director, 10% owner BVF INC/IL — Director, 10% owner LAMPERT MARK N — Director, 10% owner | Grant/award (A): 6,682 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Santos da Silva Jorge — Chief Executive Officer, Director | Grant/award (A): 95,763 @ $0 | EDGAR |
| 2025-03-03 | 4 | Reich Kristian — Chief Scientific Officer | Grant/award (A): 139,273 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Bodenstedt Matthias — Chief Financial Officer | Grant/award (A): 95,763 @ $0 | EDGAR |
Recent 8-K events — MoonLake Immunotherapeutics
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MLTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →